NO20061517L - Langvarig frigivelsesdoseingsform av Ziprasidon - Google Patents
Langvarig frigivelsesdoseingsform av ZiprasidonInfo
- Publication number
- NO20061517L NO20061517L NO20061517A NO20061517A NO20061517L NO 20061517 L NO20061517 L NO 20061517L NO 20061517 A NO20061517 A NO 20061517A NO 20061517 A NO20061517 A NO 20061517A NO 20061517 L NO20061517 L NO 20061517L
- Authority
- NO
- Norway
- Prior art keywords
- dosage form
- ziprasidone
- release dosage
- prolonged release
- oral dosage
- Prior art date
Links
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 title abstract 2
- 229960000607 ziprasidone Drugs 0.000 title abstract 2
- 239000002552 dosage form Substances 0.000 title 1
- 230000002035 prolonged effect Effects 0.000 title 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 2
- 239000006186 oral dosage form Substances 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 238000013268 sustained release Methods 0.000 abstract 1
- 239000012730 sustained-release form Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Det beskrives en fast oral doseringsform med vedvarende frigivning for behandling av en psykotisk forstyrrelse, for eksempel schizofreni, hos pattedyr. Den orale doseringsform omfatter ziprasidon i en mengde som er effektiv for behandling av nevnte psykotiske forstyrrelse, samt en fannasøytisk akseptabel bærer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49948403P | 2003-09-02 | 2003-09-02 | |
PCT/US2004/028304 WO2005020929A2 (en) | 2003-09-02 | 2004-08-31 | Sustained release dosage forms of ziprasidone |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20061517L true NO20061517L (no) | 2006-06-02 |
Family
ID=34272825
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20061517A NO20061517L (no) | 2003-09-02 | 2006-04-03 | Langvarig frigivelsesdoseingsform av Ziprasidon |
Country Status (16)
Country | Link |
---|---|
US (2) | US20070190129A1 (no) |
EP (1) | EP1663166A2 (no) |
JP (1) | JP2007504266A (no) |
KR (3) | KR20060115350A (no) |
CN (1) | CN1874761A (no) |
AR (1) | AR046811A1 (no) |
AU (1) | AU2004268663B2 (no) |
BR (1) | BRPI0414082A (no) |
CA (1) | CA2537413A1 (no) |
IL (1) | IL173866A0 (no) |
MX (1) | MXPA06002455A (no) |
NO (1) | NO20061517L (no) |
RU (1) | RU2351316C2 (no) |
TW (1) | TW200526221A (no) |
WO (1) | WO2005020929A2 (no) |
ZA (1) | ZA200601602B (no) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10179130B2 (en) | 1999-10-29 | 2019-01-15 | Purdue Pharma L.P. | Controlled release hydrocodone formulations |
AU764453B2 (en) | 1999-10-29 | 2003-08-21 | Euro-Celtique S.A. | Controlled release hydrocodone formulations |
CN101317825A (zh) | 2000-10-30 | 2008-12-10 | 欧罗赛铁克股份有限公司 | 控释氢可酮制剂 |
SG147450A1 (en) | 2003-10-29 | 2008-11-28 | Wyeth Corp | Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof |
WO2005115330A2 (en) | 2004-05-28 | 2005-12-08 | Pfizer Products Inc. | Pharmaceutical compositions with enhanced performance |
US20090142404A1 (en) * | 2004-08-31 | 2009-06-04 | Pfizer Inc | Pharmaceutical dosage forms comprising a low-solubility drug and a polymer |
EP1789022A2 (en) * | 2004-08-31 | 2007-05-30 | Pfizer Products Incorporated | Controlled release dosage forms combining immediate release and sustained release of low-solubility drug |
WO2006109177A1 (en) * | 2005-04-13 | 2006-10-19 | Pfizer Products Inc. | Injectable depot formulations and methods for providing sustained release of poorly soluble drugs comprising nanoparticles |
US20080193542A1 (en) * | 2005-04-13 | 2008-08-14 | Pfizer Inc. | Injectable Deopot Formulations and Methods For Providing Sustained Release of Nanoparticle Compositions |
EA200800092A1 (ru) * | 2005-06-20 | 2008-06-30 | Элан Фарма Интернэшнл Лимитед | Композиции в виде наночастиц и с контролируемым высвобождением, включающие арил-гетероциклические соединения |
JP2008546781A (ja) * | 2005-06-20 | 2008-12-25 | エラン・ファルマ・インターナショナル・リミテッド | アリール−複素環式化合物を含んでなるナノ粒状及び制御放出の組成物 |
US8747897B2 (en) * | 2006-04-27 | 2014-06-10 | Supernus Pharmaceuticals, Inc. | Osmotic drug delivery system |
GB2446166B (en) * | 2007-01-29 | 2010-05-12 | Teraview Ltd | A pharmaceutical analysis method and apparatus |
JP2010527925A (ja) * | 2007-05-18 | 2010-08-19 | サイドース・エルエルシー | ジプラシドン製剤 |
EP2231169B1 (en) * | 2007-12-06 | 2016-05-04 | Bend Research, Inc. | Pharmaceutical compositions comprising nanoparticles and a resuspending material |
US9233078B2 (en) | 2007-12-06 | 2016-01-12 | Bend Research, Inc. | Nanoparticles comprising a non-ionizable polymer and an Amine-functionalized methacrylate copolymer |
BRPI0909818A2 (pt) * | 2008-03-07 | 2015-10-06 | Pfizer | métodos, formas de dosagem e conjunto para administrar ziprasidona sem alimentos |
SA109300195B1 (ar) * | 2008-03-28 | 2013-04-20 | Astrazeneca Ab | تركيبة صيدلانية جديدة مضادة للسرطان |
DE102008045854A1 (de) * | 2008-09-05 | 2010-03-11 | Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg | Partikel aus Ziprasidone und einem Sprengmittel enthaltende Pharmazeutische Zusammensetzung |
CN103919742B (zh) * | 2008-11-25 | 2017-04-12 | 田边三菱制药株式会社 | 口腔速崩片及其制备方法 |
CN102234272A (zh) * | 2010-04-21 | 2011-11-09 | 上海医药工业研究院 | 盐酸齐拉西酮半水合物的制备方法 |
RU2593771C2 (ru) * | 2010-04-30 | 2016-08-10 | Такеда Фармасьютикал Компани Лимитед | Энтеросолюбильная таблетка |
US20130108701A1 (en) * | 2010-05-25 | 2013-05-02 | Krishna Murthy Bhavanasi | Solid Dosage Forms of Antipsychotics |
PL391810A1 (pl) * | 2010-07-14 | 2012-01-16 | Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna | Nowe sole ziprasidonu oraz sposoby ich otrzymywania |
CN103328089B (zh) * | 2010-12-21 | 2016-09-07 | 哈佛学院院长等 | 喷雾干燥技术 |
US8591944B2 (en) | 2011-03-08 | 2013-11-26 | Zalicus Pharmaceuticals Ltd. | Solid dispersion formulations and methods of use thereof |
US8409560B2 (en) | 2011-03-08 | 2013-04-02 | Zalicus Pharmaceuticals Ltd. | Solid dispersion formulations and methods of use thereof |
UY34856A (es) * | 2012-07-03 | 2013-12-31 | Bayer Pharma AG | Formas de presentación farmacéuticas que contienen 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4- morfolinil)-fenil]-1,3-oxazolidin-5-il}-metil)-2-tiofencarboxamida |
JP6041823B2 (ja) * | 2013-03-16 | 2016-12-14 | ファイザー・インク | トファシチニブの経口持続放出剤形 |
MX2016009427A (es) * | 2014-01-22 | 2016-12-08 | Teva Pharmaceuticals Int Gmbh | Formulaciones de pridopidina de liberacion modificada. |
EA033900B1 (ru) | 2014-02-21 | 2019-12-06 | Принсипиа Биофарма Инк. | СОЛЕВЫЕ И АМОРФНЫЕ ФОРМЫ 2-[(3R)-3-[4-АМИНО-3-(2-ФТОР-4-ФЕНОКСИФЕНИЛ)ПИРАЗОЛО[3,4-d]ПИРИМИДИН-1-ИЛ]ПИПЕРИДИН-1-КАРБОНИЛ]-4-МЕТИЛ-4-[4-(ОКСЕТАН-3-ИЛ)ПИПЕРАЗИН-1-ИЛ]ПЕНТ-2-ЕННИТРИЛА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ИХ ОСНОВЕ И СПОСОБ ЛЕЧЕНИЯ ПУЗЫРЧАТКИ ОБЫКНОВЕННОЙ И ПУЗЫРЧАТКИ ЛИСТОВИДНОЙ С ИХ ПРИМЕНЕНИЕМ |
EA036269B1 (ru) | 2014-12-18 | 2020-10-21 | Принсипиа Биофарма Инк. | Лечение пузырчатки |
BR112017013728A2 (pt) * | 2014-12-24 | 2018-03-13 | Principia Biopharma Inc. | dosagem de inibidor da btk a sítio específico |
US20180305350A1 (en) | 2015-06-24 | 2018-10-25 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
US10617650B2 (en) * | 2015-10-16 | 2020-04-14 | Merck Sharp & Dohme Corp. | Process for preparing formulations for gastrointestinal-targeted therapies |
US20190231784A1 (en) | 2016-06-29 | 2019-08-01 | Principia Biopharma Inc. | Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile |
US20180147153A1 (en) * | 2016-11-28 | 2018-05-31 | Johnson & Johnson Consumer Inc. | Process for making a coated dosage form |
CN109725092A (zh) * | 2019-03-19 | 2019-05-07 | 北京和合医学诊断技术股份有限公司 | 检测血液中齐拉西酮含量的液相色谱分析方法 |
CA3198795A1 (en) * | 2020-11-18 | 2022-05-27 | Jeffrey Becker | Complexing agent salt formulations of pharmaceutical compounds |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2261678A (en) * | 1937-06-17 | 1941-11-04 | Westinghouse Electric & Mfg Co | Electrical flasher system |
US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
NZ248813A (en) * | 1992-11-25 | 1995-06-27 | Eastman Kodak Co | Polymeric grinding media used in grinding pharmaceutical substances |
US5560932A (en) * | 1995-01-10 | 1996-10-01 | Nano Systems L.L.C. | Microprecipitation of nanoparticulate pharmaceutical agents |
US5874029A (en) * | 1996-10-09 | 1999-02-23 | The University Of Kansas | Methods for particle micronization and nanonization by recrystallization from organic solutions sprayed into a compressed antisolvent |
IL126590A (en) * | 1996-05-07 | 2001-11-25 | Pfizer | Trihydrate salt of -5 (-2 (-4 (1 (2, 2-benzothiazole - 3yl) -1-piperazinyl) ethyl) - 6-chloro-1, 3-dihydro-2 (1H) - indole - 2On (= Ziprasidone) and pharmaceutical preparations containing it |
UA57734C2 (uk) * | 1996-05-07 | 2003-07-15 | Пфайзер Інк. | Комплекси включення арилгетероциклічних солей |
GB9706714D0 (en) * | 1997-04-02 | 1997-05-21 | Reckitt & Colman Inc | Improvements in or relating to organic compositions |
US6046177A (en) * | 1997-05-05 | 2000-04-04 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations |
GB9711643D0 (en) * | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
EP0901786B1 (en) * | 1997-08-11 | 2007-06-13 | Pfizer Products Inc. | Solid pharmaceutical dispersions with enhanced bioavailability |
UA72189C2 (uk) * | 1997-11-17 | 2005-02-15 | Янссен Фармацевтика Н.В. | Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот |
US20030059471A1 (en) * | 1997-12-15 | 2003-03-27 | Compton Bruce Jon | Oral delivery formulation |
US6150366A (en) * | 1998-06-15 | 2000-11-21 | Pfizer Inc. | Ziprasidone formulations |
EP1027885B1 (en) * | 1999-02-09 | 2008-07-09 | Pfizer Products Inc. | Basic drug compositions with enhanced bioavailability |
US6706283B1 (en) * | 1999-02-10 | 2004-03-16 | Pfizer Inc | Controlled release by extrusion of solid amorphous dispersions of drugs |
US7030142B1 (en) * | 1999-04-06 | 2006-04-18 | Sepracor Inc. | Methods for the treatment of neuroleptic and related disorders using ziprasidone metabolites |
DE60038698T2 (de) * | 1999-12-23 | 2009-05-07 | Pfizer Products Inc., Groton | Hydrogel-gesteuerte dosierungsform |
EP1712222A3 (en) * | 1999-12-23 | 2012-06-20 | Pfizer Products Inc. | Pharmaceutical compositions providing enhanced drug concentrations |
US6352721B1 (en) * | 2000-01-14 | 2002-03-05 | Osmotica Corp. | Combined diffusion/osmotic pumping drug delivery system |
US6753011B2 (en) * | 2000-01-14 | 2004-06-22 | Osmotica Corp | Combined diffusion/osmotic pumping drug delivery system |
EP1269994A3 (en) * | 2001-06-22 | 2003-02-12 | Pfizer Products Inc. | Pharmaceutical compositions comprising drug and concentration-enhancing polymers |
US20040062778A1 (en) * | 2002-09-26 | 2004-04-01 | Adi Shefer | Surface dissolution and/or bulk erosion controlled release compositions and devices |
WO2004037289A2 (en) * | 2002-10-25 | 2004-05-06 | Pfizer Products Inc. | Novel injectable depot formulations |
US20040121003A1 (en) * | 2002-12-19 | 2004-06-24 | Acusphere, Inc. | Methods for making pharmaceutical formulations comprising deagglomerated microparticles |
TW200500067A (en) * | 2003-01-21 | 2005-01-01 | Control Delivery Sys Inc | Salts of codrugs and uses related thereto |
CA2525366A1 (en) * | 2003-05-16 | 2004-11-25 | Pfizer Products Inc. | Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines |
US20050038047A1 (en) * | 2003-08-14 | 2005-02-17 | Edwards Paul John | Azaquinazoline derivatives |
WO2005065660A2 (en) * | 2003-12-31 | 2005-07-21 | Alpharma, Inc. | Ziprasidone formulations |
US20080305161A1 (en) * | 2005-04-13 | 2008-12-11 | Pfizer Inc | Injectable depot formulations and methods for providing sustained release of nanoparticle compositions |
US20080193542A1 (en) * | 2005-04-13 | 2008-08-14 | Pfizer Inc. | Injectable Deopot Formulations and Methods For Providing Sustained Release of Nanoparticle Compositions |
-
2004
- 2004-08-31 CA CA002537413A patent/CA2537413A1/en not_active Abandoned
- 2004-08-31 KR KR1020067004186A patent/KR20060115350A/ko not_active Application Discontinuation
- 2004-08-31 JP JP2006526153A patent/JP2007504266A/ja active Pending
- 2004-08-31 MX MXPA06002455A patent/MXPA06002455A/es unknown
- 2004-08-31 AU AU2004268663A patent/AU2004268663B2/en not_active Ceased
- 2004-08-31 TW TW093126238A patent/TW200526221A/zh unknown
- 2004-08-31 KR KR1020087024649A patent/KR20080093464A/ko not_active Application Discontinuation
- 2004-08-31 EP EP04782731A patent/EP1663166A2/en not_active Withdrawn
- 2004-08-31 BR BRPI0414082-6A patent/BRPI0414082A/pt not_active IP Right Cessation
- 2004-08-31 CN CNA2004800284347A patent/CN1874761A/zh active Pending
- 2004-08-31 AR ARP040103123A patent/AR046811A1/es unknown
- 2004-08-31 WO PCT/US2004/028304 patent/WO2005020929A2/en active Application Filing
- 2004-08-31 US US10/931,143 patent/US20070190129A1/en not_active Abandoned
- 2004-08-31 RU RU2006106464/15A patent/RU2351316C2/ru not_active IP Right Cessation
- 2004-08-31 KR KR1020097014042A patent/KR20090080143A/ko not_active Application Discontinuation
-
2006
- 2006-02-21 IL IL173866A patent/IL173866A0/en unknown
- 2006-02-23 ZA ZA200601602A patent/ZA200601602B/en unknown
- 2006-04-03 NO NO20061517A patent/NO20061517L/no not_active Application Discontinuation
-
2009
- 2009-09-03 US US12/261,678 patent/US20100003331A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
BRPI0414082A (pt) | 2006-10-24 |
CA2537413A1 (en) | 2005-03-10 |
US20100003331A1 (en) | 2010-01-07 |
IL173866A0 (en) | 2006-07-05 |
MXPA06002455A (es) | 2006-08-31 |
KR20060115350A (ko) | 2006-11-08 |
ZA200601602B (en) | 2007-05-30 |
KR20090080143A (ko) | 2009-07-23 |
CN1874761A (zh) | 2006-12-06 |
AU2004268663A1 (en) | 2005-03-10 |
US20070190129A1 (en) | 2007-08-16 |
AR046811A1 (es) | 2005-12-28 |
TW200526221A (en) | 2005-08-16 |
RU2006106464A (ru) | 2007-09-10 |
JP2007504266A (ja) | 2007-03-01 |
AU2004268663B2 (en) | 2010-12-09 |
KR20080093464A (ko) | 2008-10-21 |
WO2005020929A3 (en) | 2005-08-25 |
EP1663166A2 (en) | 2006-06-07 |
RU2351316C2 (ru) | 2009-04-10 |
WO2005020929A2 (en) | 2005-03-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20061517L (no) | Langvarig frigivelsesdoseingsform av Ziprasidon | |
DE60022226D1 (de) | Benzimidazolverbindungen die nociceptinrezeptoraffinität haben | |
BRPI0413152A (pt) | derivados de benzimidazol alquilado por n3 como inibidores de mek | |
EA201000563A1 (ru) | Триазолпиридиновые ингибиторы 11-бета- гидроксистероид - дегидрогеназы типа i | |
IS8503A (is) | Azatvíhringja heteróhringir sem kannabínóníð-viðtakastillar | |
PA8501801A1 (es) | Inhibidores triciclicos de polimerasas (adp - polirribosas) | |
DK1689724T3 (da) | Quinazolinonforbindelser som anticancermidler | |
NO20052787D0 (no) | N-alkyl-4-metylenamino-3-hydroksy-2-pyridoner som antimikrobielle midler | |
MX2007003329A (es) | Derivados heterociclicos y biciclicos y su uso como inhibidores de estearoil-coa-desaturasa (scd). | |
ATE302775T1 (de) | Carbolinderivate | |
NO20062256L (no) | Hydroksyalkylsubstituerte pyrido-7-pyrimidin-7-oner | |
DE602005023197D1 (de) | -muscarinrezeptors | |
NO331012B1 (no) | N-sulfonyl-4-metylenamino-3-hydroksy-2-pyridoner som antimikrobielle midler | |
ECSP088966A (es) | Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia | |
NO20065873L (no) | 3-(4-(2-dihydroisoksazol-3-ylpyridin-5-yl)fenyl)-5-triazol-1-ylmetyloksoazolidin-2-on derivater som MAO inhibitorer i behandlingen av bakterielle infeksjoner | |
DE602005007765D1 (de) | Neue indol- oder benzimidazol-derivate | |
EA200501697A1 (ru) | Дозируемая форма, содержащая пантопразол в качестве активного ингредиента | |
ATE333457T1 (de) | Zyklische gmp-spezifische phosphodiesteraseinhibitoren | |
DK1305037T3 (da) | Smertestillende medikament | |
PL390683A1 (pl) | Zastosowanie pochodnych pirolu do wytwarzania leku | |
AR027349A1 (es) | Derivados de amidas heterociclicas | |
ATE360422T1 (de) | Tetrazyklische verbindungen als pde5-inhibitoren | |
EA200400877A1 (ru) | 2'-гало-3',5'-диалкоксифен-1'-илимино-2-имидазолидиновые производные и их применение для лечения недержания мочи | |
NO20081818L (no) | Arylsulfonylkromaner som 5-HT6-inhibitorer - indolylmaleimidderivater som protein kinaseinhibitorer | |
DE10394330D2 (de) | Quellsubstratpellets als orale Darreichungsform für Ballaststoffe |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |